[The results of metronidazole use in radiation and combined treatment of patients with laryngeal cancer].
The paper is concerned with the results of radiation and combined therapy of 153 laryngeal cancer patients. Of them 103 received radiotherapy combined with metronidazole at a dose of 5-8 g/m2 2.5-3 h before an irradiation session, 50 patients were controls. Radiotherapy was given by mean fractions at a dose of 5 Gy 2 times a week with a summary focal dose of 20 Gy with subsequent irradiation at a daily dose of 2 Gy up to a summary dose of 32 Gy. The efficacy of radiotherapy was evaluated after a 2-week discontinuation. In a complete resorption or lessening of a tumor volume by more than 70% radiotherapy was continued by conventional fractionation at a daily dose of 2 Gy up to a summary focal dose of 52 Gy. In insignificant lessening of a tumor volume the patients were operated on. The use of metronidazole in a radical course of radiotherapy of laryngeal cancer patients did not improve therapeutic results, however the number of postoperative complications caused by surgical treatment for tumor recurrences increased 3 times. In combined treatment of the laryngeal cancer patients after a summary focal dose of 32 Gy and 1.5-3 years of follow-up the number of the patients increased up to 75.7% as compared to 50% in the control group. A decrease in the number of postoperative complications was noted.
D000328:Adult; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D007825:Laryngectomy; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage
D008795:Metronidazole
Rezul'taty primeneniia metronidazola pri luchevom i kombinirovannom lechenii bol'nykh rakom gortani.